Enanta Pharmaceuticals Inc (ENTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.16 Million) by net assets ($116.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Enanta Pharmaceuticals Inc (ENTA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Enanta Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Enanta Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ratchthani Leasing Public Company Limited
BK:THANI
|
0.127x |
|
Worldex Industry & Trading Co. Ltd
KQ:101160
|
-0.002x |
|
BlackRock California Municipal Income Closed Fund
NYSE:BFZ
|
-0.060x |
|
Novabase SGPS
LS:NBA
|
0.059x |
|
Campine
BR:CAMB
|
0.436x |
|
Radiant Logistics Inc
NYSE MKT:RLGT
|
0.011x |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
0.054x |
|
Race Oncology Ltd
AU:RAC
|
-0.093x |
Annual Cash Flow Conversion Efficiency for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Enanta Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Enanta Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $64.72 Million | $-19.27 Million | -0.298x | +51.30% |
| 2024-09-30 | $128.81 Million | $-78.76 Million | -0.611x | -28.47% |
| 2023-09-30 | $216.74 Million | $-103.15 Million | -0.476x | -80.39% |
| 2022-09-30 | $321.33 Million | $-84.78 Million | -0.264x | -50.56% |
| 2021-09-30 | $399.43 Million | $-70.00 Million | -0.175x | -1226.35% |
| 2020-09-30 | $455.58 Million | $7.09 Million | 0.016x | -89.92% |
| 2019-09-30 | $462.49 Million | $71.42 Million | 0.154x | +108.05% |
| 2018-09-30 | $393.68 Million | $29.22 Million | 0.074x | -57.47% |
| 2017-09-30 | $301.68 Million | $52.65 Million | 0.175x | +31.57% |
| 2016-09-30 | $269.94 Million | $35.81 Million | 0.133x | -59.14% |
| 2015-09-30 | $236.16 Million | $76.67 Million | 0.325x | +139.18% |
| 2014-09-30 | $148.65 Million | $20.18 Million | 0.136x | +40.76% |
| 2013-09-30 | $110.47 Million | $10.65 Million | 0.096x | -81.27% |
| 2012-09-30 | $43.93 Million | $22.62 Million | 0.515x | +382.94% |
| 2011-09-30 | $-131.96 Million | $24.02 Million | -0.182x | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more